Einstein/Montefiore Department of Medicine

Grand Rounds

Medicine Grand Rounds: Psoriatic Arthritis: Pathogenesis and Therapeutic Paradigms

Einstein/Montefiore Department of Medicine Grand Rounds

Thursday, November 19, 2015

8:00 AM: Forchheimer Medical Science Building 3rd Floor Lecture Hall

Speaker & Info

Christopher Ritchlin, MD, MPH
Professor of Medicine, University of Rochester School of Medicine & Dentistry
Division Chief, Allergy, Immunology & Rheumatology, University of Rochester School of Medicine & Dentistry
Director, Clinical Immunology Research Center, URMC

Repeated at 12:15 pm, Cherkasky Auditorium, Montefiore Medical Center.

Dr. Christopher Ritchlin's basic science research efforts are directed towards understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic arthritis and rheumatoid arthritis. Using a translational approach, investigators in his lab are analyzing the cell surface molecules expressed by osteoclast and dendritic cell precursors with the goal to identify susceptibility and response biomarkers in patients with inflammatory arthritis. The lab is also studying the effect of anti-TNF agents on dendritic cell differentiation in RA and PsA patients. Collaborative studies are underway with the lab of Dr. Eddie Schwarz to understand the mechanisms that are responsible for bone marrow edema as recorded on magnetic resonance imaging scans in inflammatory arthritis. The bulk of this work is performed in animal models but insights gained from these studies are applied to the study of human joint diseases such as psoriatic and rheumatoid arthritis.

Dr. Ritchlin is the Director of the Clinical Immunology Research Unit where he is the principle investigator on several clinical trials testing the efficacy of anti-TNF agents and other biologic molecules in the treatment of psoriatic and rheumatoid arthritis and ankylosing spondylitis. In the Clinical Immunology Research Unit, patient-oriented research is conducted on multiple levels. Investigator New Drug (IND) trials of novel agents (adalimumab, rituximab) in the treatment of PsA and AS have been completed or are about to start. Additional trials have been performed to study the effect of TNF inhibition on the frequency of osteoclast precursors and enhancing bone marrow edema in PsA. The Unit also conducts multicenter trials with novel biologic agents such as rituximab and abatacept in PsA with special attention directed towards understanding how these agents alter bone remodeling in these disorders. Studies underway include microanalysis assays of synovium, skin and intestinal tissues in patients with Immune Mediated Inflammatory Disroders (IMIDs) before and after TNF inhibition. Future plans include the development of ultrasound outcome measures in collaboration with Dr. Ralf Thiele and Dr. Darren Tabechian, to assess synovial, lymph node and periarticular tissue responses to different therapies in inflammatory arthritis.

Objectives - After attending this activity, participants will be able to:

  1. Discuss parallel disease mechanisms in psoriasis and PsA
  2. Outline steps that can be taken to identify PsA at earlier stages
  3. Understand emerging treatment paradigms for PsA

Accreditation: Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity. Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Host: Division of Rheumatology (Department of Medicine)

Contact Us

Department of Medicine
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
Belfer Building - Room 1008
1300 Morris Park Avenue
Bronx, NY 10461 (directions)

Physicians and Patients:
866-MED-TALK (866-633-8255)

Internal Medicine Residency Program:
718-920-6097

Administrative Questions:
718-430-2591
Fax: 718-430-8659

 
Click here to log in